Better Buy: Teladoc vs. Amwell
In this video I will be going over Teladoc's (NYSE: TDOC) recent earnings and comparing it to one of its competitors, Amwell (NYSE: AMWL). While one's business has been improving, the other's has been declining. You can find the full video below.
Teladoc Health's organic revenue grew by 41% vs. 69% sequentially. The company reported total revenue of $503 million, up 108.7% year over year and 10.8% quarter over quarter.
The company expects Q3 revenue to come in between $510 million and $520 million, a 78% YOY growth at the midpoint, and total visits to be between 3.4 million and 3.6 million, a 23.5% YOY growth at the midpoint.
Source Fool.com
